Clinical trials are ongoing for the first long-lasting, reversible male birth control which is the first innovation in male birth control since the vasectomy hit the scene in 1897. This week’s Found guest is Kevin Eisenfrats, the co-founder and CEO of Contraline, a biotech company developing innovative methods to use hydrogel as a contraceptive. Contraline’s first product, ADAM, is what some are calling the first male IUD. The company will begin clinical trials in the U.S. very soon.

In this conversation they cover:

• The process of fundraising when you’re creating a completely new category
• Why the overturning of Roe V. Wade has led to increased interest in ADAM by men in the US
• The future of Contraline and other innovations that use hydrogels

(0:00) Introduction

(2:26) The challenges to male birth control

(6:53) Why hydrogel works

(9:35) Developing ADAM

(15:08) Cultural reaction to ADAM

(20:18) Entrepreneurship in medicine

(22:39) FDA approval process

(28:09) What’s next for Contraline

(34:23) Host conversation

Found posts every Tuesday. Subscribe on Apple, Spotify or wherever you listen to podcasts to be alerted when new episodes drop. Check out the other TechCrunch podcast: Equity . Subscribe to Found to hear more stories from founders each

Connect with us:

• On Twitter
• On Instagram
• Via email: found@techcrunch.com